BBIO
BridgeBio Pharma Inc
NASDAQ: BBIO · HEALTHCARE · BIOTECHNOLOGY
$70.94
+1.76% today
Updated 2026-04-29
Market cap
$13.75B
P/E ratio
—
P/S ratio
27.39x
EPS (TTM)
$-3.78
Dividend yield
—
52W range
$32 – $85
Volume
2.5M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A7.0
Quality
B+2.0
Profitability
F6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-5.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$100.89
+42.22%
12-Month target
—
—
Intrinsic (DCF)
$502.53
Margin of safety
+85.41%
5 Strong Buy16 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 2,521.00% QoQ
+ 85.41% below intrinsic value
+ Debt/equity -0.96x — low leverage
Risks
- Altman Z -5.88 — distress zone
- Thin margins at -144.40%
- Negative free cash flow $-60.95M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $77.65M | $9.30M | $221.90M | $502.08M | $502.08M |
| Net income | $-481.18M | $-643.20M | $-535.76M | $-729.31M | $-197.24M |
| EPS | — | — | — | — | $-3.78 |
| Free cash flow | $-425.81M | $-529.03M | $-521.66M | $-447.01M | $-60.95M |
| Profit margin | -619.70% | -6,913.92% | -241.44% | -145.26% | -144.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-10 | KUMAR, NEIL | Sale | 20,000 | $74.60 |
| 2026-04-09 | KUMAR, NEIL | Sale | 7,800 | $75.53 |
| 2026-04-09 | KUMAR, NEIL | Sale | 7,500 | $75.55 |
Peer comparison
Smart narrative
BridgeBio Pharma Inc trades at $70.94. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -5.88, it sits in the distress. TTM revenue stands at $502.08M. with profit margins at -144.40%. Our DCF model estimates intrinsic value at $502.53.
Frequently asked questions
What is BridgeBio Pharma Inc's stock price?
BridgeBio Pharma Inc (BBIO) trades at $70.94.
Is BridgeBio Pharma Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell). DCF value $502.53.
What is the price target of BridgeBio Pharma Inc (BBIO)?
The analyst target price is $100.89, representing +42.2% upside from the current price of $70.94.
What is the intrinsic value of BridgeBio Pharma Inc (BBIO)?
Based on our DCF model, intrinsic value is $502.53, a +85.4% margin of safety versus $70.94.
What is BridgeBio Pharma Inc's revenue?
TTM revenue is $502.08M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-5.88 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio27.39x
ROE-1,790.00%
Beta1.09
50D MA$71.28
200D MA$64.16
Shares out0.19B
Float0.16B
Short ratio—
Avg volume2.5M
Performance
1 week-1.02%
1 month-4.47%
3 months-10.32%
YTD-7.26%
1 year—
3 years—
5 years—